These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 18616811

  • 1. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
    Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A.
    BMC Cancer; 2008 Jul 10; 8():195. PubMed ID: 18616811
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan 10; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

  • 3. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
    Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, Sliwa T, Poehnl R, Buxhofer-Ausch V, Strecker K, Hoermann G, Knoebl P, Jaeger U, Geissler K, Kundi M, Valent P.
    Am J Hematol; 2017 Oct 10; 92(10):E567-E574. PubMed ID: 28699225
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
    Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A, Hotta T, Tamura K.
    Br J Haematol; 2016 Aug 10; 174(4):563-70. PubMed ID: 27072050
    [Abstract] [Full Text] [Related]

  • 5. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC.
    J Clin Oncol; 2003 Feb 01; 21(3):514-9. PubMed ID: 12560443
    [Abstract] [Full Text] [Related]

  • 6. A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
    Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E, Nicolini F, Troncy J, Barraco F, Michallet M, Thomas X.
    Hematology; 2010 Jun 01; 15(3):125-31. PubMed ID: 20557669
    [Abstract] [Full Text] [Related]

  • 7. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
    Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W.
    Blood; 2009 Apr 23; 113(17):3903-10. PubMed ID: 19131552
    [Abstract] [Full Text] [Related]

  • 8. Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
    Wang X, Clowes C, Duarte R, Pu QQ.
    Int J Oncol; 2000 Sep 23; 17(3):591-5. PubMed ID: 10938403
    [Abstract] [Full Text] [Related]

  • 9. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
    Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.
    Ann Oncol; 2002 Jun 23; 13(6):903-9. PubMed ID: 12123336
    [Abstract] [Full Text] [Related]

  • 10. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec 23; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB, Kido A.
    Clin Pharmacokinet; 2011 May 23; 50(5):295-306. PubMed ID: 21456630
    [Abstract] [Full Text] [Related]

  • 12. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.
    Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A.
    Blood; 1997 Dec 15; 90(12):4710-8. PubMed ID: 9389686
    [Abstract] [Full Text] [Related]

  • 14. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 15; 10(3):186-91. PubMed ID: 20511163
    [Abstract] [Full Text] [Related]

  • 15. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep 15; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

  • 16. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J.
    Semin Oncol; 2003 Aug 15; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [Abstract] [Full Text] [Related]

  • 17. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.
    Leuk Res; 2008 Dec 15; 32(12):1800-8. PubMed ID: 18621416
    [Abstract] [Full Text] [Related]

  • 18. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
    Zhang W, Jiang Z, Wang L, Li C, Xia J.
    Med Oncol; 2015 May 15; 32(5):147. PubMed ID: 25820754
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 15; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
    Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
    Clin Cancer Res; 2009 Dec 01; 15(23):7361-7. PubMed ID: 19920107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.